compunded semaglutide FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable products FDA Warns on Certain Forms

Such observations raise safety concerns about GLP-1 RAs

However, many providers recommend stopping 1-2 months before attempting pregnancy to ensure complete clearance

In the SURMOUNT trials for tirzepatide, researchers used an escalation starting at 2.5 mg weekly, increasing by 2.5 mg every four weeks until reaching the target maintenance dose (typically 5 mg, 10 mg, or 15 mg)

doi: 10.1007/s00125-018-4669-0

Roche's public obesity strategy, as of April 2026, centers on CT-388 (a GLP-1/GIP dual acquired through the Carmot Therapeutics acquisition) and a deep orforglipron-competitor oral GLP-1 program

However, long-term use is likely necessary, as stopping the medication often leads to weight regain